Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Artificial Intelligence Research of Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
1 other identifier
observational
500
1 country
1
Brief Summary
This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 13, 2022
CompletedStudy Start
First participant enrolled
November 20, 2022
CompletedFirst Posted
Study publicly available on registry
November 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedNovember 22, 2022
July 1, 2022
5 months
November 13, 2022
November 21, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Tumor Grade
Tumor Grade based on 2021 WHO central nervous system tumor guideline
up to 2 weeks
Tumor Histologic diagnosis
Tumor histologic diagnosis based on 2021 WHO central nervous system tumor guideline
up to 2 weeks
Tumor genotype
Tumor genotype based on 2021 WHO central nervous system tumor guideline
up to 2 weeks
Study Arms (3)
Glioblastoma Group
Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.
Astrocytoma Group
Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.
Oligodendroglioma Group
Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.
Interventions
Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
Eligibility Criteria
Patients with diagnosis of adult diffuse glioma who recevived tumor rection surgery in our center
You may qualify if:
- Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05 with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma.
- Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences
- No pre-surgery anti-tumor therapy
You may not qualify if:
- Poor image quality
- Failed image preprocessing
- Unavailable pathology data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University
Nanjing, Jiangsu, 210093, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 13, 2022
First Posted
November 22, 2022
Study Start
November 20, 2022
Primary Completion
May 1, 2023
Study Completion
May 1, 2025
Last Updated
November 22, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share
We don't plan to share IPD with other researches